Opus Genetics, Inc. (IRD): debt financing — Opus Genetics closes $35 million initial tranche of $155 million senior secured notes

Opus Genetics, Inc.

Initial $35 million tranche funded on April 21, 2026; notes mature April 21, 2033.
Notes bear floating rate based on Term SOFR (with floor) plus margin; interest payable quarterly.
Total note purchase agreement provides up to $155 million ($105M committed, $50M uncommitted).
Notes secured by substantially all assets of Opus Genetics and its subsidiaries.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Opus Genetics, Inc. incurred senior notes of $35 million with OPCM SA LLC at floating rate based on Term SOFR, subject to a floor maturing April 21, 2033.

Instrument: senior notes
Principal: $35 million
Counterparty: OPCM SA LLC
Rate: floating rate based on Term SOFR, subject to a floor
Maturity: April 21, 2033
Event: incurrence

Exact text from the filing

The initial tranche of $35 million was funded, and Notes in the aggregate amount of $35 million (the “Initial Tranche Notes”) were issued, on April 21, 2026.

View on SEC.gov

71 debt financings filed in the last 30 days. Browse all debt financings →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-016764

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.